Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration
复制标题
血浆磷酸化tau181对阿尔茨海默病和额颞叶变性的诊断价值
DOI：
10.1038/s41591-020-0762-2
复制
发表时间：
2020-03-02
期刊：
影响因子：
82.9
通讯作者：
Boxer, Adam L.
中科院分区：
文献类型：
--
作者：
Thijssen, Elisabeth H.;La Joie, Renaud;Boxer, Adam L.
与诊断为额颞叶变性或老年对照的患者相比，血浆pTau 181浓度在诊断为阿尔茨海默病的患者中特别升高，支持其作为AD的基于血液的生物标志物的进一步发展。随着新的疾病修饰阿尔茨海默病（AD）疗法的潜在发展，需要简单，广泛可用的筛选测试来识别哪些个体，出现认知或行为下降症状的患者，应进一步评估是否开始治疗。与目前批准的脑脊液或淀粉样蛋白β正电子发射断层扫描（PET）诊断测试相比，基于血液的AD测试将是一种侵入性较小且成本较低的筛查工具。我们研究了血浆tau蛋白残基181磷酸化（pTau 181）是否可以区分临床诊断或尸检证实的AD和额颞叶变性。与对照组相比，AD患者血浆pTau 181浓度增加了3.5倍，并将AD与临床诊断（受试者操作特征曲线下面积为0.894）和尸检证实的额颞叶变性（曲线下面积为0.878）区分开来。血浆pTau 181鉴定了淀粉样蛋白β-PET阳性的个体，无论临床诊断如何，并且与通过F-18-flortaucipir PET测量的皮质tau蛋白沉积相关。血浆pTau 181可用于筛选与AD相关的tau病理学。
Plasma pTau181 concentrations are elevated specifically in patients diagnosed with Alzheimer's disease compared to those diagnosed with frontotemporal lobar degeneration or elderly controls, supporting its further development as a blood-based biomarker for AD.With the potential development of new disease-modifying Alzheimer's disease (AD) therapies, simple, widely available screening tests are needed to identify which individuals, who are experiencing symptoms of cognitive or behavioral decline, should be further evaluated for initiation of treatment. A blood-based test for AD would be a less invasive and less expensive screening tool than the currently approved cerebrospinal fluid or amyloid beta positron emission tomography (PET) diagnostic tests. We examined whether plasma tau phosphorylated at residue 181 (pTau181) could differentiate between clinically diagnosed or autopsy-confirmed AD and frontotemporal lobar degeneration. Plasma pTau181 concentrations were increased by 3.5-fold in AD compared to controls and differentiated AD from both clinically diagnosed (receiver operating characteristic area under the curve of 0.894) and autopsy-confirmed frontotemporal lobar degeneration (area under the curve of 0.878). Plasma pTau181 identified individuals who were amyloid beta-PET-positive regardless of clinical diagnosis and correlated with cortical tau protein deposition measured by F-18-flortaucipir PET. Plasma pTau181 may be useful to screen for tau pathology associated with AD.